This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cutaneous T cell lymphoma (CTCL)	Janus kinase-3 (JAK3; JAK-3)	<p>Studies in mice suggest that inhibiting JAK-3 could be useful for treating lymphoid malignancies including CTCL. In a murine bone marrow transplantation model, transduction with a highly expressed variant of JAK-3 induced an aggressive, fatal lymphoproliferative phenotype compared with that seen in mice transduced with wild-type, constitutively expressed JAK-3. Next steps include determining the implications of these findings for CTCL patients with the same JAK-3 variant used in the study.</p> <p>CP-690,550, an oral JAK-3 inhibitor from Pfizer Inc., is in Phase II testing to treat rheumatoid arthritis (RA) and graft rejection.</p> <p>R348, a JAK-3 inhibitor from Rigel Pharmaceuticals Inc., is in Phase I testing for RA.</p> <p>VX-509, a JAK-3 inhibitor from Vertex Pharmaceuticals Inc., is in Phase I testing to treat autoimmune disease and preclinical testing for RA and psoriasis.</p> <p>SciBX 2(4); doi:10.1038/scibx.2009.136 Published online Jan. 29, 2009</p>	Patent and licensing status unavailable	<p>Cornejo, M. <i>et al. Blood</i>; published online Jan. 12, 2009; doi:10.1182/blood-2008-06-164368</p> <p>Contact: Thomas Mercher, Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France e-mail: thomas.mercher@inserm.fr</p>